CompanyBLTENasdaqSan Diego, CA

Belite Bio, Inc

Belite Bio develops tinlarebant, an oral small molecule that reduces bisretinoid accumulation by modulating serum retinol levels, for Stargardt disease type 1 and geographic atrophy.

Stories only

SEC EDGAR ClinicalTrials.gov belitebio.com

10-KSep 9Latest SEC filing, period to Jun 30

Sep 8Latest story

September 2026

Belite Bio files Japan NDA for tinlarebant in Stargardt disease type 1

Sep 8Regulatory milestoneBelite Bio, Inc tinlarebant

August 2026

Belite Bio posts Q2 2026 results as FDA reviews tinlarebant NDA under priority review

Aug 12Regulatory milestoneBelite Bio, Inc tinlarebant